Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

In silico to in vivo splicing analysis using splicing code models.

Gazzara MR, Vaquero-Garcia J, Lynch KW, Barash Y.

Methods. 2014 May 1;67(1):3-12. doi: 10.1016/j.ymeth.2013.11.006. Epub 2013 Dec 7.

2.

Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.

Fugier C, Klein AF, Hammer C, Vassilopoulos S, Ivarsson Y, Toussaint A, Tosch V, Vignaud A, Ferry A, Messaddeq N, Kokunai Y, Tsuburaya R, de la Grange P, Dembele D, Francois V, Precigout G, Boulade-Ladame C, Hummel MC, Lopez de Munain A, Sergeant N, Laquerrière A, Thibault C, Deryckere F, Auboeuf D, Garcia L, Zimmermann P, Udd B, Schoser B, Takahashi MP, Nishino I, Bassez G, Laporte J, Furling D, Charlet-Berguerand N.

Nat Med. 2011 Jun;17(6):720-5. doi: 10.1038/nm.2374. Epub 2011 May 29.

PMID:
21623381
3.

Altered splicing of the BIN1 muscle-specific exon in humans and dogs with highly progressive centronuclear myopathy.

Böhm J, Vasli N, Maurer M, Cowling BS, Shelton GD, Kress W, Toussaint A, Prokic I, Schara U, Anderson TJ, Weis J, Tiret L, Laporte J.

PLoS Genet. 2013 Jun;9(6):e1003430. doi: 10.1371/journal.pgen.1003430. Epub 2013 Jun 6. Erratum in: PLoS Genet. 2013 Jun;9(6). doi:10.1371/annotation/22ca13f1-1ce9-4bb5-9c9e-98670f7c4240. Cowling, Belinda [corrected to Cowling, Belinda S].

4.

Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing.

Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC.

J Biol Chem. 1997 Dec 12;272(50):31453-8.

5.

Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.

Kennah E, Ringrose A, Zhou LL, Esmailzadeh S, Qian H, Su MW, Zhou Y, Jiang X.

Blood. 2009 May 7;113(19):4646-55. doi: 10.1182/blood-2008-08-174037. Epub 2009 Feb 10.

6.

A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants.

Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, Lu Y, Seet BT, Katz S, Szyperski T, Penn LZ, Arrowsmith CH.

J Mol Biol. 2005 Aug 5;351(1):182-94.

PMID:
15992821
7.
8.

N-WASP is required for Amphiphysin-2/BIN1-dependent nuclear positioning and triad organization in skeletal muscle and is involved in the pathophysiology of centronuclear myopathy.

Falcone S, Roman W, Hnia K, Gache V, Didier N, Lainé J, Auradé F, Marty I, Nishino I, Charlet-Berguerand N, Romero NB, Marazzi G, Sassoon D, Laporte J, Gomes ER.

EMBO Mol Med. 2014 Nov;6(11):1455-75. doi: 10.15252/emmm.201404436.

9.

Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.

Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC.

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9689-94.

10.

AVISPA: a web tool for the prediction and analysis of alternative splicing.

Barash Y, Vaquero-Garcia J, González-Vallinas J, Xiong HY, Gao W, Lee LJ, Frey BJ.

Genome Biol. 2013;14(10):R114.

11.

Tissue-specific alternative splicing remodels protein-protein interaction networks.

Ellis JD, Barrios-Rodiles M, Colak R, Irimia M, Kim T, Calarco JA, Wang X, Pan Q, O'Hanlon D, Kim PM, Wrana JL, Blencowe BJ.

Mol Cell. 2012 Jun 29;46(6):884-92. doi: 10.1016/j.molcel.2012.05.037.

12.

Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein.

Markovtsov V, Nikolic JM, Goldman JA, Turck CW, Chou MY, Black DL.

Mol Cell Biol. 2000 Oct;20(20):7463-79.

13.

Splicing code modeling.

Barash Y, Vaquero-Garcia J.

Adv Exp Med Biol. 2014;825:451-66. doi: 10.1007/978-1-4939-1221-6_13. Review.

PMID:
25201114
14.

Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies.

Toussaint A, Cowling BS, Hnia K, Mohr M, Oldfors A, Schwab Y, Yis U, Maisonobe T, Stojkovic T, Wallgren-Pettersson C, Laugel V, Echaniz-Laguna A, Mandel JL, Nishino I, Laporte J.

Acta Neuropathol. 2011 Feb;121(2):253-66. doi: 10.1007/s00401-010-0754-2. Epub 2010 Oct 7.

PMID:
20927630
15.

Identification of a novel effector domain of BIN1 for cancer suppression.

Lundgaard GL, Daniels NE, Pyndiah S, Cassimere EK, Ahmed KM, Rodrigue A, Kihara D, Post CB, Sakamuro D.

J Cell Biochem. 2011 Oct;112(10):2992-3001. doi: 10.1002/jcb.23222.

16.

Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.

Jia Y, Wang H, Wang Y, Wang T, Wang M, Ma M, Duan Y, Meng X, Liu L.

Int J Cancer. 2015 Sep 1;137(5):1095-106. doi: 10.1002/ijc.29481. Epub 2015 Apr 28.

17.

Differential alternative splicing activity of isoforms of polypyrimidine tract binding protein (PTB).

Wollerton MC, Gooding C, Robinson F, Brown EC, Jackson RJ, Smith CW.

RNA. 2001 Jun;7(6):819-32.

18.

Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma.

Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC.

Int J Cancer. 2000 Apr 15;86(2):155-61.

20.

Supplemental Content

Support Center